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Downstream of MAPKs, such as classical/atypical ERKs and p38 MAPKs, but not
of JNKs, signaling is often mediated by protein kinases which are phosphorylated
and activated by MAPKs and, therefore, designated MAPK-activated protein kinases
(MAPKAPKs). Recently, novel insights into the specificity of the assembly of
MAPK/MAPKAPK hetero-dimeric protein kinase signaling complexes have been gained.
In addition, new functional aspects of MKs have been described and established
functions have been challenged. This short review will summarize recent developments
including the linear motif (LM) in MKs, the ERK-independent activation of RSK, the
RSK-independent effects of some RSK-inhibitors and the challenged role of MK5/PRAK
in tumor suppression.
Keywords: p38 MAPK, ERK3/4, common docking motif, macrophage-specific activation, dendritic cells, mouse
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INTRODUCTION
Besides phosphorylation of other substrates, ERKs and p38 MAPKs are able to signal further
downstream by the activation of so called MAPK-activated protein kinases (MAPKAPKs)
(reviewed in Cargnello and Roux, 2011). These downstream kinases are the p90 ribosomal-
S6-kinases (RSK1-3), the mitogen- and stress-activated protein kinases MSK1/2, the MAPK-
interacting kinases MNK1/2 and the MAPKAP kinases MK2, MK3 and MK5/PRAK (Gaestel,
2006). Specific signaling complexes between MAPK and their target MAPKAPKs exist and are the
structural basis for the functional downstream-extension of MAPK cascades. Canonical activation
pathways have been defined for the exclusive activation of RSKs by ERK1/2, the exclusive activation
of MK2/3 by p38α/β as well as the more promiscuous activation of MNKs andMSKs by both ERKs
and p38 and of MK5/PRAK by p38β/ERK3/4. Here, I will discuss novel findings regarding the
molecular basis of specific and productive signaling complexes between MAPKs and MAPKAPKs,
the non-canonical activation of RSKs and recent challenges arising from off target effects of the
widely used RSK inhibitors SL0101 and BI-D1870. Furthermore, the challenge of the anticipated
tumor-suppressive function of MK5/PRAK is discussed.
NOVEL INSIGHTS
The Molecular Basis for MAPKAPK’s Specific Interaction with
MAPKs: Classical D Motifs and Reverse D-Motifs Constitute the
Linear Motif (LM)
Specific interactions of MAPKs with their activators and substrates are established via the common
docking (CD) motif of MAPKs (D-X2-D/E) and the docking (D) motif (R/K-R/K-X2−6-Ø-X-Ø) or
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kinase-interacting motif (KIM) (L/V-X2-R/K-R/K-X5-L) of the
substrate or activator (Tanoue et al., 2000; reviewed in Gaestel,
2008). However, while these interactions fully govern the
recognition and phosphorylation of unstructured regions in
substrates such as transcription factors, the CD-D-interaction
is not completely sufficient for establishing the specificity of
binding of MAPKs to important activators and other substrates.
The isolated D-motifs of MKK3/6 (p38 specific MAPKK) or
MKK1/2 (ERK specific MAPKK) are, for instance, not able
to discriminate between p38α and ERK2, but bind to both
kinases with comparable affinity (Garai et al., 2012). Further
structural analyses have revealed that the CD motif of MAPKs
can be divided into the negatively charged CD groove and
various further hydrophobic pockets or grooves which are able
to interact with the basic core of the D-motif and a pattern
of further hydrophobic residues located N terminal to the D-
motif designated reverse D (revD) motif (Ø-X-Ø-X2-Ø-X4−6-Ø-
X2-R/K-R/K) (Garai et al., 2012). Interestingly, this revD motif
allows clear discrimination in binding affinity between p38α and
ERK2. While the revD motif of RSK1 displays high affinity to
ERK2, its binding affinity to p38α is 20-fold lower. Vice versa, the
revD motif of MK2 shows strong affinity to p38α but only weak
interaction with ERK2 (Garai et al., 2012).
Only the revD of MNK1, which is activated by both ERK2
and p38α, displays similar affinity to both kinases. Hence, a
linear motif (LM) formed by the overlapping D and revD motifs
is necessary and sufficient to guarantee specific interaction in
the binary MAPK/MAPKAPK complexes such as ERK2/RSK1
and p38α/MK2. The following alignment shows the D-, KIM-,
and revD motifs identified in MAPK substrates and activators.
Together, these overlapping motifs should be regarded as the
linear motif (LM). Ø stands for a hydrophobic amino acid, Xn
for the number n of variable amino acids:
D: R/K-R/K-X2−6-Ø-X-Ø
KIM: L/V-X2-R/K-R/K-X5-L
revD: Ø-X-Ø-X2-Ø-X4−6-Ø-X2-R/K-R/K
LM: Ø-X-Ø-X2-Ø-X4-6-Ø-X2-R/K-R/K-X2-6-Ø-X-Ø
Although the CD motif-LM-interaction is essential for various
MAPK/MAPKAPK complexes, the CD-motif of the atypical
MAPKs ERK 3 and ERK4 is not sufficient for the activation of
MK5/PRAK. Instead, a novel FRIEDE interaction motif in loop
L16 C-terminal to the CD-motif is necessary for MK5/PRAK
binding of ERK3/4 (Aberg et al., 2009). Interestingly, the L16
FRIEDE motif in ERK3/4 is activated by phosphorylation of
the atypical activation loop SEG in an allosteric manner. The
FRIEDE motif interacts with the C-terminus of MK5/PRAK and
a mutant lacking 50 C-terminal amino acids but still containing
the D-domain of MK5/PRAK is unable to bind to ERK3/4 (Aberg
et al., 2006). Hence, this interaction is clearly different from the
CD-LM-module.
Primary MAPK/MAPKAPK Complexes
Formed by LM-CD Motif Interaction
The binding of the LM of a MAPKAPK and the CD grooves
of MAPKs (Figures 1A,B) is the first step of formation of
specific signaling complexes but does not necessarily lead
FIGURE 1 | Schematic representation of the postulated steps to reach
signaling competent, fully active binary kinase complexes between
MAPKs (here p38α) and MAPKAPKs (here MK2). The features of the five
different states postulated (A–E) are depicted at the right.
to the formation of a signaling competent complex with
both MAPK and MAPKAPK activity. However, the primary
“encounter” complex formation (Figure 1B) is already able to
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cause mutual stabilization of the MAPKs/MAPKAPKs in the
specific complex. In vivo, this stabilization is reflected by the
findings that in non-stimulated MK2-deficient cells the p38α
level is significantly reduced (Kotlyarov et al., 2002) and that
p38α-deficient resting cells display reduced MK2 levels (Sudo
et al., 2005). Furthermore, the formation of primary, non-
productive kinase complexes is able to prevent binding to
(and activation by) non-specific MAPKs and crosstalk with
other signaling pathways. This is demonstrated in vitro by
the fact that addition of inactive p38α strongly increases the
specificity of ppERK2 toward RSK1 and blocks ppERK2’s activity
against MK2 (Alexa et al., 2015). This finding implies that the
stoichiometry between specific MAPKs and MAPKAPKs is an
important determinant to maintain the specificity of signaling
also in vivo. Taking into account that other MAPK substrates and
activators compete with MAPKAPKs in binding to the CDmotif,
signaling complex formation in vivo is likely highly sensitive to
the local concentrations of these competing interactors. In this
regard a high complexity of regulation will also arise due to
the fact that local sub-cellular concentrations of many signaling
molecules are also signal-regulated. Equal importantly, this result
also indicates that artificial overexpression of a specific MAPK
or MAPKAPK, which can lead to significant stoichiometric
alterations between specific MAPKs and/or MAPKAPKs in
the cell, could also lead to artificial activation of non-specific
signaling pathways. This would explain the initial observation
that MK3, a kinase downstream to p38α/β, is activated by
ERKs, JNKs, and p38 in cells overexpressing these MAPKs
(Ludwig et al., 1996) or that MK5/PRAK, a kinase activated
by the atypical ERK3/4 (see below), also displays docking
to p38α when both kinases are overexpressed (New et al.,
2003).
The three-dimensional structure of a primary MAPK-
MAPKAPK-complex between non-phosphorylated p38α/MK2
has been established (White et al., 2007). In this complex
the LM of MK2 is bound to the CD motif of p38α.
Both kinases bind in a parallel “head to head” orientation
(Figure 1B), but catalytic and substrate regions are distantly
located at different sides of the kinase heterodimer making it
unlikely that this is a signaling competent complex. However,
this orientation would enable upstream activators, such as
MKK3 or MKK6, to phosphorylate the activation loop of
p38α leading to a semi-phosphorylated primary complex
(Figure 1C).
Productive Dimerization Leading to Active
Signaling Complexes
The three-dimensional structure of another non-phosphorylated
MAPK/MAPKAPK complex consisting of ERK2 and RSK1 has
recently been determined revealing a structure for a pre-catalytic
state of anti-parallel “head to tail” orientation where both kinases
face each other and the activation loop of RSK2 is located
close to the catalytic center of ERK2 (Alexa et al., 2015). After
phosphorylation of ERK2 by the upstream activatorMEK1/2 only
minor readjustments of the orientation of the binary complex
seem necessary to activate RSK1 by phosphorylation of the
CTD leading to a productive signaling module (Alexa et al.,
2015).
In the case of p38α/MK2more complex changes in orientation
of the molecules in the complex seem necessary to enable
p38 to phosphorylate the regulatory sites of MK2 (Figure 1D).
It could be assumed that these changes are allosterically
induced by phosphorylation of p38α at the activation loop.
After phosphorylation of the regulatory sites of MK2 at the
activation loop and in the hinge region between catalytic core
and C-terminal extension, MK2 itself undergoes a structural
transition involving a major conformational change of the
atypically structured APE motif of MK2 (Alexa et al., 2015).
As a result of this process a fully active signaling complex
is formed (Figure 1E). The transition from the primary
“encounter” complex to the fully active p38α/MK2 signaling
complex is accompanied by a reduction of the affinity of
interaction reflected by a increase of the Kd-value from 2.5 nM
for non-phosphorylated MK2 and p38α to about 60 nM for
phosphorylated MK2 and p38α (Lukas et al., 2004). Interestingly,
a number of proteins and cellular structures, such as LIMK1
(Kobayashi et al., 2006), keratin K8/K20, or K8/K18 complexes
(Menon et al., 2010) and the neighboring immediate early
promoter binding factors CREB/SRF (Heidenreich et al., 1999;
Ronkina et al., 2011) are substrates for both p38α and
MK2 indicating that the fully active p38α/MK2 complex
might act cooperatively to phosphorylate these proteins and
structures.
Non-Canonical Activation of RSK in
Dendritic Cells
Although there is a specific interaction between ERKs and
RSKs via the CD-LM-interaction in many cell types, an ERK-
independent but p38α-dependent activation of RSK by MK2
and MK3 has been described in dendritic cells. In these
cells MK2/3 bypass phosphorylation of the C-terminal kinase
domain (KD) by ERKs by directly phosphorylating the auto-
phosphorylation site S386 between N- and C-terminal KD, a
prerequisite for the activation of the N-terminal KD by PDK1
(Zaru et al., 2007). Recently, the structural and functional
basis for the cell type-specific operation of this alternative
activation mechanism of RSKs has been characterized further
(Zaru et al., 2014). It has turned out that the non-canonical
activation of RSKs is specific for hematopoietic cells, such
as dendritic cells and macrophages, and that the C-terminal
KD of RSK is dispensable for this activation. Furthermore,
the existence of the non-canonical activation mechanism
is accompanied by an increased constitutive cytoplasmic
localization of p38α/MK2/3 in these cells and a very low
activation of ERKs by inflammatory stimuli, such as LPS. Hence,
in these cells a certain plasticity of MAPK signaling guarantees
the LPS-induced TLR-mediated interferon-β induction via the
p38α/MK2/3-RSK-pathway. The interaction betweenMK2/3 and
RSK in these cells seems rather transient (Zaru et al., 2014)
and it is not clear whether further cell type-specific protein
partners facilitate this interaction in macrophages and dendritic
cells.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 January 2016 | Volume 3 | Article 88
Gaestel MAPKAPKs: Novel Insights and Challenges
ESTABLISHED FUNCTIONS CHALLENGED
Challenged Specificity of the Compounds
BI-D1870 and SL0101 and
mTORC1-Related Function of RSKs
In tests against a panel of recombinant protein kinases the
compounds BI-D1870 and SL0101 appeared as relatively specific
inhibitors for RSK1 and RSK2 (Bain et al., 2007). However,
said panel did not contain mTOR or mTORC1 and a recent
study demonstrated that BI-D1870 and SL0101 also modulate
mTORC1-p70S6K signaling in different directions (Roffé et al.,
2015). Since SL0101 clearly also inhibits mTORC1-p70S6K
signaling, the demonstration that RSK phosphorylates ribosomal
protein S6, a substrate of p70S6K, using this inhibitor is
challenged. Interestingly, BI-D1870 increased p70S6K activation
in an ERK1/2- and RSK-independent manner by a mechanism
unknown to date. In the light of these findings, the interpretation
of the results presented in nearly 100 publications describing
effects of these inhibitors without confirming these effects by
further experiments, such as knockdown or overexpression of
active kinase, should be reassessed. Meanwhile, novel and more
specific RSK-inhibitors have also been identified (Jain et al.,
2015) enabling us to better define the in vivo function of these
kinases.
Challenged Function of MK5/PRAK as
Tumor Suppressor
Controversial discussions regarding the activation mechanism
and function of MK5/PRAK have been published. As seen from
the LM alignment below, the sequence of the LM present in this
protein kinase bears similarity to both the LM of RSK and MK2,
indicating possible interaction with ERKs or p38 MAPKs:
RSK1: 721-PQLKPIESSILAQRRVRKLPS-741
:::. .. .: .
MK5/PRAK: 348-VSLKPLHSVNNPILRKRKLLGTK-364
. .: . . ::.: ::. .
MK2: 372-IKIKKIEDASNPLLLKRRKKARA-392
LM: ØXØXXØXXXXXXØXXRRXXXØXØ
KK
In line with this similarity, activation of MK5/PRAK has been
observed by p38 MAPKs and by ERKs when these kinases
were overexpressed in mammalian cells (New et al., 1998;
Ni et al., 1998). Furthermore, there is the FRIEDE-binding
region (see above) in the C-terminal stretch of 50 amino
acids, which enables interaction of this kinase with ERK3/4
(Aberg et al., 2009). Overexpression of both p38α and ERK3/4
leads to phosphorylation of MK5/PRAK at its regulatory site
T182 and its activation as measured by phosphorylation of
the peptide PRAKtide. While several publications describe a
p38-dependent activation of MK5/PRAK (New et al., 1998),
others could not detect activation of MK5/PRAK by stimuli,
which activate p38 MAPKs, such as arsenite or high osmolarity
(sorbitol) treatment (Shi et al., 2003). ERK3/4 activity and
binding of the FRIEDE motif to MK5/PRAK can be stimulated
TABLE 1 | Comparison of the results of the targeting approaches for
MK5/PRAK.
“MK5 knockout” (Shi
et al., 2003)
“PRAK knockout” (Sun
et al., 2007)
MK5/PRAK targeting
strategy
Deletion of exon 6 (1ex6) Deletion of exon 8 (1ex8)
Protein Truncated, deletion of 30
amino acids (131–160)
Truncated, deletion of 27
amino acids (194–220)
Stability Instable Stable (similar to WT)
Localization Cytoplasmic Nuclear (similar to WT)
Kinase domain Subdomains VIa, VIb
missing
Stretch between subdomains
VIII and IX shortened
Kinase activity Not-detectable Residual autophosphorylation
Reduction of
H-Ras-G12V-induced
p21WAF expression in
targeted MEFs
− +
Ras-induced
tumorigenity/growth of
targeted MEFs in soft
agar
− +
Increased skin tumor
formation in the one
step DMBA model in
the targeted mouse
strain
− +
by phosphorylation by p21-activated kinase 1 (PAK1) in the SEG
motif in the activation loop (De la Mota-Peynado et al., 2011;
Déléris et al., 2011) connecting MK5 to signaling of the small
GTP-ase Rac. Furthermore, acetylation of MK5/PRAK at lysine
K364 in the putative LM has also been described to increase
its activity, although it should interfere with binding of the
appropriate MAPK (Zheng et al., 2013), and various substrates
of MK5/PRAK, such as p53 (Sun et al., 2007), HSP27 (Kostenko
et al., 2009), FoxO3a (Kress et al., 2011), Foxo1 (Chow et al.,
2013), and Rheb (Zheng et al., 2011) have been proposed.
The function of MK5/PRAK has been mainly characterized
by two different mouse knockout approaches targeting exon
6 and exon 8, respectively (Shi et al., 2003; Sun et al.,
2007). Surprisingly, it has recently turned out that both
knockout approaches for MK5/PRAK failed to delete the entire
protein (Ronkina et al., 2015). Instead, two different truncated
MK5/PRAK forms are still present in the knockout mice
(Table 1). Since these mutants display different biochemical
and cellular properties (Table 1) it is not surprising that the
effects of expression of these mutants in cellular systems
differ: While MEFs from the 1ex6-targeted mice did not show
altered p21WAF level in response to H-Ras-G12V expression
and did not grow in soft agar, 1ex8-targeted MEFs displayed
reduced levels of the key marker of tumor suppression p21WAF
and growth in soft agar (Sun et al., 2007; Ronkina et al.,
2015). It is highly probable that the properties of the different
MK5/PRAK deletion mutants also contribute to the phenotype
of the targeted mice in the established DMBA one-step skin
tumor model. Hence, it is not surprising that 1ex6-targeted
mice did not display increased skin tumor formation in this
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model, while 1ex8-targeted did (Sun et al., 2007; Ronkina
et al., 2015). Since the results obtained using the 1ex8-targeted
mice formed the basis for the formulation of the tumor
suppressive role of MK5/PRAK (Sun et al., 2007) as well as
for the identification of MK5/PRAK as a tumor-promoting
angiogenic factor (Yoshizuka et al., 2012), these roles are
challenged and should be revisited by MK5 targeting approaches
deleting the entire protein kinase. Once the phenotype of the
real MK5/PRAK knockout mouse has been described, these
results should serve to clarify the physiological function of
MK5/PRAK.
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